Insulet Co. (NASDAQ:PODD) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Insulet Co. (NASDAQ:PODD) have been given an average recommendation of “Moderate Buy” by the fifteen analysts that are covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $253.27.

A number of research analysts have commented on the company. Canaccord Genuity Group boosted their target price on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Barclays increased their price objective on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Raymond James lifted their target price on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Morgan Stanley increased their price target on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Finally, UBS Group lifted their price objective on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th.

Insulet Trading Up 0.4 %

Insulet stock opened at $262.93 on Friday. Insulet has a 12 month low of $160.19 and a 12 month high of $279.40. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock has a market cap of $18.44 billion, a P/E ratio of 45.02, a P/E/G ratio of 4.01 and a beta of 1.22. The company’s fifty day simple moving average is $241.32 and its 200-day simple moving average is $210.77.

Institutional Investors Weigh In On Insulet

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC bought a new stake in Insulet during the 3rd quarter valued at approximately $616,000. TD Private Client Wealth LLC boosted its stake in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares during the period. Teachers Retirement System of The State of Kentucky boosted its stake in Insulet by 3.4% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 36,054 shares of the medical instruments supplier’s stock valued at $8,393,000 after purchasing an additional 1,189 shares during the period. Toronto Dominion Bank grew its stake in shares of Insulet by 15.3% in the third quarter. Toronto Dominion Bank now owns 23,502 shares of the medical instruments supplier’s stock worth $5,470,000 after acquiring an additional 3,117 shares during the last quarter. Finally, Coldstream Capital Management Inc. increased its position in Insulet by 144.5% during the third quarter. Coldstream Capital Management Inc. now owns 2,893 shares of the medical instruments supplier’s stock worth $714,000 after acquiring an additional 1,710 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.